Zentalis Pharmaceuticals
ZNTL · NASDAQ
$2.39+$0.09 (+3.91%)TodayMarket closed ·
Prev close $2.30
Who owns ZNTL
Largest institutional holders, from their latest 13F filings
The 10 largest institutions hold 60.1% of ZNTL’s shares.
- Walters Group25.1%
- 5AM Ventures5.5%
- Squadron Capital Management LLC5.2%
- BlackRock Institutional Trust Company, N.A.4.9%
- Next 6 largest institutions19.5%
- All other shareholders39.9%
| Holder | Shares | % of shares |
|---|---|---|
| Walters Group | 17.84M | 25.07% |
| 5AM Ventures | 3.95M | 5.55% |
| Squadron Capital Management LLC | 3.70M | 5.20% |
| BlackRock Institutional Trust Company, N.A. | 3.46M | 4.86% |
| Two Sigma Investments, LP | 3.02M | 4.25% |
| Vanguard Capital Management, LLC | 2.84M | 3.98% |
| Acadian Asset Management LLC | 2.68M | 3.77% |
| Citadel Advisors LLC | 2.30M | 3.23% |
| Renaissance Technologies LLC | 1.61M | 2.26% |
| Opaleye Management Inc. | 1.41M | 1.98% |
Largest mutual fund holders
| Holder | Shares | % of shares |
|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.19M | 3.07% |
| iShares Russell 2000 ETF | 1.23M | 1.73% |
| Franklin Templeton Investment Funds -Biotechnology Discovery | 759.26K | 1.07% |
| PRIMECAP Odyssey Aggressive Growth Fund | 676.40K | 0.95% |
| Vanguard Extended Market Index Fund | 575.85K | 0.81% |
Insider trades
Form 4 filings by officers, directors and large holders
Over the last 6 months, insiders bought $15.17M (1 trade) of ZNTL on the open market, with no sales.
| Insider | Type | Shares | Value |
|---|---|---|---|
| Bruns Ingmar | Award | 9.73K | $21.20K |
| WALTERS GROUP | Buy | 4.33M | $15.17M |
| Myers Scott Dunseth | Award | 57.10K | — |
| Campbell Shannon | Award | 114.20K | — |
Short interest
Settled Sep 30, 2026
- Shares short
- 5.96M
- Days to cover
- 4.13
- % of shares outstanding
- 8.37%
- Average daily volume
- 1.44M
- Change since last report
- +24.5%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.